このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Eris Lifesciences バランスシートの健全性
財務の健全性 基準チェッ ク /26
Eris Lifesciencesの総株主資本は₹32.2B 、総負債は₹27.4Bで、負債比率は84.9%となります。総資産と総負債はそれぞれ₹70.5Bと₹38.3Bです。 Eris Lifesciencesの EBIT は₹4.9Bで、利息カバレッジ比率5.8です。現金および短期投資は₹14.0Bです。
主要情報
84.9%
負債資本比率
₹27.35b
負債
| インタレスト・カバレッジ・レシオ | 5.8x |
| 現金 | ₹14.01b |
| エクイティ | ₹32.22b |
| 負債合計 | ₹38.27b |
| 総資産 | ₹70.49b |
財務の健全性に関する最新情報
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20Recent updates
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Investor Optimism Abounds Eris Lifesciences Limited (NSE:ERIS) But Growth Is Lacking
Aug 22Eris Lifesciences Limited (NSE:ERIS) Looks Interesting, And It's About To Pay A Dividend
Aug 08Should You Buy Eris Lifesciences Limited (NSE:ERIS) For Its Upcoming Dividend?
Aug 08財務状況分析
短期負債: ERISの 短期資産 ( ₹23.0B ) は 短期負債 ( ₹25.3B ) をカバーしていません。
長期負債: ERISの短期資産 ( ₹23.0B ) が 長期負債 ( ₹12.9B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: ERISの 純負債対資本比率 ( 41.4% ) は 高い と見なされます。
負債の削減: ERISの負債対資本比率は、過去 5 年間で15.1%から84.9%に増加しました。
債務返済能力: ERISの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 17.8% )。
インタレストカバレッジ: ERISの負債に対する 利息支払い は EBIT ( 5.8 x coverage) によって 十分にカバーされています。